BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Dick Van Dyke shares his secrets to longevity as he turns 100 - 2Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- 3‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism
- 4NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- 5Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road
- Top 15 Supportable Design Brands Coming out on top
- Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- 'Sex and the City' star Kim Cattrall marries longtime partner Russell Thomas in intimate London wedding
- Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- UN panel says Israel operating 'de facto policy of torture'
